Cargando…
Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. The current study investigated the outcomes in ATC patients treated by paclitaxel as neoadjuvant setting. Furthermore, the prognostic factor for overall survival (OS) and predictive marker for response to...
Autores principales: | Yamazaki, Haruhiko, Sugino, Kiminori, Katoh, Ryohei, Matsuzu, Kenichi, Masaki, Chie, Akaishi, Junko, Hames, Kiyomi Yamada, Tomoda, Chisato, Suzuki, Akifumi, Ohkuwa, Keiko, Kitagawa, Wataru, Nagahama, Mitsuji, Rino, Yasushi, Ito, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939216/ https://www.ncbi.nlm.nih.gov/pubmed/36052510 http://dx.doi.org/10.1002/cam4.5219 |
Ejemplares similares
-
Preoperative inflammatory markers for predicting parathyroid carcinoma
por: Ohkuwa, Keiko, et al.
Publicado: (2022) -
Risk stratification in differentiated thyroid cancer with RAI-avid lung metastases
por: Ohkuwa, Keiko, et al.
Publicado: (2021) -
Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2020) -
MON-552 Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma
por: Akaishi, Junko, et al.
Publicado: (2019) -
Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
por: Masaki, Chie, et al.
Publicado: (2021)